Sarcomas are rare tumors derived from mesenchymal tissues including bone, muscle, and adipose tissues. They represent less than 1% of total cancers in the US and therapies for sarcoma relative to more common carcinoma have lagged behind. Within a given sarcoma type, there are multiple subtypes and this heterogeneity complicates the development of therapies. Because these tumors are so diverse, it is unlikely that there is a one-size-fits-all therapeutic approach. New approaches are likely to be based on subtypes, and may even need to be highly personalized.
Sarcoma genotypes may be simple (specific genetic alterations such as chromosomal translocations or other mutational drivers) or complex (multiple genomic alterations, such as rearrangements and duplications). Currently, risk factors for sarcomas are better predicted by the size of the tumor than based on their genetics. Therapies are based on tumor histology.
A greater understanding of the best use of existing therapies and new therapies could provide better treatment for sarcoma patients with a poor prognosis.
The goal of this Research Topic is to provide an up-to-date summary of new targets, therapeutics, and strategies for the treatment of sarcomas. This would include both cutting-edge technologies as well as utilizing known approaches in a more effective manner. Sarcomas are heterogeneous, so we will try to highlight therapies that can be utilized across multiple sarcoma types as well as those limited to a particular type. Treatment may be targeted based on genetics, histology, or both.
We welcome Original Research Articles, Review Articles, Brief Communication, Opinions, and Case Reports that explore the current landscape of new and established therapeutic approaches in sarcomas. This might include:
- genetics of sarcomas and general vs subtype vs personalized medicine
- targeted therapies
- immunotherapy
- use of existing chemotherapies, surgical, and radiation approaches
- recent success and recent failures
- animal models of sarcoma and translational studies
- biomarkers - predictive and pharmacodynamic
We welcome both preclinical and clinical studies.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Sarcomas are rare tumors derived from mesenchymal tissues including bone, muscle, and adipose tissues. They represent less than 1% of total cancers in the US and therapies for sarcoma relative to more common carcinoma have lagged behind. Within a given sarcoma type, there are multiple subtypes and this heterogeneity complicates the development of therapies. Because these tumors are so diverse, it is unlikely that there is a one-size-fits-all therapeutic approach. New approaches are likely to be based on subtypes, and may even need to be highly personalized.
Sarcoma genotypes may be simple (specific genetic alterations such as chromosomal translocations or other mutational drivers) or complex (multiple genomic alterations, such as rearrangements and duplications). Currently, risk factors for sarcomas are better predicted by the size of the tumor than based on their genetics. Therapies are based on tumor histology.
A greater understanding of the best use of existing therapies and new therapies could provide better treatment for sarcoma patients with a poor prognosis.
The goal of this Research Topic is to provide an up-to-date summary of new targets, therapeutics, and strategies for the treatment of sarcomas. This would include both cutting-edge technologies as well as utilizing known approaches in a more effective manner. Sarcomas are heterogeneous, so we will try to highlight therapies that can be utilized across multiple sarcoma types as well as those limited to a particular type. Treatment may be targeted based on genetics, histology, or both.
We welcome Original Research Articles, Review Articles, Brief Communication, Opinions, and Case Reports that explore the current landscape of new and established therapeutic approaches in sarcomas. This might include:
- genetics of sarcomas and general vs subtype vs personalized medicine
- targeted therapies
- immunotherapy
- use of existing chemotherapies, surgical, and radiation approaches
- recent success and recent failures
- animal models of sarcoma and translational studies
- biomarkers - predictive and pharmacodynamic
We welcome both preclinical and clinical studies.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
